Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Primary Biliary Cirrhosis (PBC)
NCT01389973Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2011
- Primary completion
- Jun 2013
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ustekinumab in primary biliary cholangitis (PBC) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Alkaline Phosphatase Response at 12 weeks. Started Sep 2011; status: completed.
02
Drugs
ustekinumab
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT01389973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01389973.